BridgeBio Oncology Therapeutics
BBOT· Manufacturing· Fiscal year ends in December
No proxy on file names the CEO of BridgeBio Oncology Therapeutics.
Executives3
See all- 1Yong Ben, M.D., M.B.A.Chief Medical and Development OfficerFY2024
- 2Eli Wallace, Ph.D.Former President and Chief Executive OfficerNot disclosed
- 3Uneek Mehra, M.B.A.Former Chief Financial OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allBridgeBio Oncology Therapeutics paid its one named executive on file $1.5M in FY2024 (Dec).
| Name | |
|---|---|
| Yong Ben, M.D., M.B.A.Chief Medical and Development Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for BridgeBio Oncology Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
No new filings about this company in the feed.
Filings3
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Annual report | 10-K | Mar 11, 2025 | FY2024 |
